Multicultural Marketing

Reach Your Target Audience and Maximize Your Brand’s Impact.

Learn More
mcm1

Multicultural Marketing Consulting for Life Sciences

Your Brand, Your Product, Your Messaging in Their Language

Whether you’re a corporation looking to adapt and target your branding, marketing, and advertising for new markets, or an agency working toward these goals on a client’s behalf, TransPerfect Life Sciences' multicultural marketing solutions help ensure maximum impact for your efforts.

Life Sciences Multicultural Consulting

Successful globalization requires more than just translation—it requires an in-depth understanding of the local culture and regulations. Regardless of the market you’re expanding into, if you’re a healthcare marketing agency, a patient recruitment agency, or life sciences organization, our specialized team of multilingual brand managers and global consultants will keep your brand and product commercialization on track.

Content & Campaign Adaption

Building an effective campaign means hours of work and detailed planning. When you’re expanding globally, adapting every single aspect of your messaging can be a monumental challenge. Ensure that your campaign and content stay true to your core messaging while meeting your launch expectations with expert insights into your target audience and cultural nuances—all while adhering to local market regulations.

Specialized Brand, Marketing, and Advertising Global Consulting for the Life Sciences Industry

Whether you’re entering a new market for the first time or finding ways to improve your global expansion, we have the experience and expertise to help you effectively adapt your product’s messaging to capture the local nuances of any market.

Maximize Your Brand’s Impact

Get a free consultation.

How did you hear about us?
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

News and Thought Leadership

Our industry experts have in-depth understanding of the challenges, requirements, and goals for life sciences organizations.

LifeSci Talks COA Series | Are We Sacrificing Good for Perfect in Clinical Outcome Assessment?

In this episode of LifeSci Talks, Mark Wade, Global Practice Leader at TransPerfect Life Sciences, sits down with Stacie Hudgens, Chief Scientific and Strategy Officer at Clinical Outcome Solutions, to discuss whether the field of clinical outcome assessment has started sacrificing “good for perfect.” Together, they explore the role of regulatory guidance and clinical development timelines, specifically the role of measurement science in already tight development ...

LifeSci Talks COA Series | Are We Sacrificing Good for Perfect in Clinical Outcome Assessment?

C3 Summit 2025 - London

Conversations on Clinical Content, C3 Summit is part of a series of events hosted by TransPerfect Life Sciences featuring sessions with expert panels discussing present challenges, strategies, and innovations, as well as insights into future advancements, from R&D to ...

Libraries in Clinical Outcome Assessments: How Valuable Are They—and Are They the Panacea They’re Claimed to Be?

Speed, cost, and quality are competing priorities in eCOA localization. Discover why translation libraries alone aren't enough, and what combination of proactive licensing, automation, and integrated technology can transform your deployment timelines. ...

From Reactive to Strategic: How AI Is Transforming Medical Information Contact Centers

IntroductionFor decades, Medical Information (MI) has been an essential function within pharma, but largely a reactive one. This is especially true in medical information contact centers, which serve as the first line of support for HCPs and patients. When someone has a...

Is AI Ready to Transform COA Development?

AI is reshaping clinical development, but its greatest value may lie not in replacing human expertise, but rather in augmenting it. Across the drug development pipeline, AI is helping teams analyze vast datasets faster, identify promising compounds earlier, and uncover...

Five Domains the FDA Wants You to Measure in PROs for Cancer—and Why Translation Affects All of Them

In a recent "LifeSci Talks" episode, TransPerfect Global Practice Leader Mark Wade and Signant Health VP and eCOA Scientist Bill Byrom PhD discussed how new FDA guidance is reshaping how sponsors approach patient-reported outcomes (PROs) in cancer clinical trials. PROs...

AI in Medical Information: Challenges, Opportunities, and the Path to Compliant Content at Scale

Medical information teams are being asked to do more with less; faster turnaround, broader content demands, and zero tolerance for inaccuracy. AI offers a way forward, but adoption comes with real challenges: how do you validate accuracy, integrate literature review, and build ...